Skip to main content
SpringerLink
Log in

Serum levels of TUBB3 correlate with clinical outcome in Chinese patients with advanced gastric cancer receiving first-line paclitaxel plus capecitabine

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

The overexpression of β-tubulin III (TUBB3) in tumor tissues was reversely related with the efficacy of paclitaxel and clinical outcome in different cancers. In this study, we aimed to investigate the association between serum levels of TUBB3 and clinical outcome in advanced gastric cancer patients receiving first-line paclitaxel plus capecitabine. One hundred and twenty-eight advanced gastric cancer patients receiving first-line paclitaxel plus capecitabine in Peking University Cancer Hospital from December 2006 to October 2010 were enrolled in the study. Serum samples from 32 healthy individuals were used as controls. TUBB3 expression level in advanced gastric cancer was significantly higher than that in healthy control group (31.6 ± 17.8 ng/mL vs. 16.9 ± 3.8 ng/mL, p < 0.001). For all patients, the clinical benefit rate (CBR), median progression-free survival (PFS), and overall survival (OS) were 55.6 %, 179 and 306 days, respectively. The CBR, median PFS, and OS in patients with low (n = 27) and high levels (n = 101) of TUBB3 were 95.8 %/45.1 % (low vs. high, p < 0.001), 190 days/166 days (p = 0.064), and 360 days/297 days (p = 0.023), respectively. Cox multivariate regression analysis demonstrated that the serum levels of TUBB3 were an independent prognostic factor for advanced gastric cancer patients (HR = 1.950; 95 % CI, 1.242–3.062; p = 0.004). This study indicated that low levels of TUBB3 in serum could predict better response and survival for advanced gastric cancer patients receiving paclitaxel plus capecitabine, which could be used to select patients who would benefit from this regimen.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–917.

    Article  PubMed  CAS  Google Scholar 

  2. Lustosa SA, Saconato H, Atallah ÁN. Lopes Filho Gde J, Matos D. Impact of extended lymphadenectomy on morbidity, mortality, recurrence and 5-year survival after gastrectomy for cancer: meta-analysis of randomized clinical trials. Acta Cir Bras. 2008;23(6):520–30.

    Article  PubMed  Google Scholar 

  3. Kang HJ, Chang HM, Kim TW, Ryu MH, Sohn HJ, Yook JH, Oh ST, Kim BS, Lee JS, Kang YK. A phase II study of paclitaxel and capecitabine as a first-line combination chemotherapy for advanced gastric cancer. Br J Cancer. 2008;98(2):316–22.

    Article  PubMed  CAS  Google Scholar 

  4. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol. 2006;24(18):2903–9.

    Article  PubMed  CAS  Google Scholar 

  5. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama W, Toh Y, Nagaie T, Takagi S, Yamamura Y, Yanaoka K, Orita H, Takeuchi M. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9(3):215–21.

    Article  PubMed  CAS  Google Scholar 

  6. Ajani JA, Rodriguez W, Bodoky G, Moiseyenko V, Lichinitser M, Gorbunova V, Vynnychenko I, Garin A, Lang I, Falcon S. Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol. 2010;28(9):1547–53.

    Article  PubMed  CAS  Google Scholar 

  7. Bokemeyer C, Hartmann J, Lampe C, Clemens M, Quietzsch D, Forkmann L, Kanz L. Paclitaxel and weekly 24-hour infusion of 5-fluorouracil/folinic acid in advanced gastric cancer. Semin Oncol. 1997;24(6 suppl 19):S19–96, S19–100.

    Google Scholar 

  8. Kollmannsberger C, Quietzsch D, Haag C, Lingenfelser T, Schroeder M, Hartmann JT, Baronius W, Hempel V, Clemens M, Kanz L, Bokemeyer C. A phase II study of paclitaxel, weekly, 24-hour continuous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer. Br J Cancer. 2000;83(4):458–62.

    Article  PubMed  CAS  Google Scholar 

  9. Park SR, Oh DY, Kim DW, Kim TY, Heo DS, Bang YJ, Kim NK, Kang WK, Kim HT, Im SA, Suh JH, Kim HK, Kim HK. A multi-center, late phase II clinical trial of Genexol (paclitaxel) and cisplatin for patients with advanced gastric cancer. Oncol Rep. 2004;12(5):1059–64.

    PubMed  CAS  Google Scholar 

  10. Sakamoto J, Matsui T, Kodera Y. Paclitaxel chemotherapy for the treatment of gastric cancer. Gastric Cancer. 2009;12(2):69–78.

    Article  PubMed  CAS  Google Scholar 

  11. Gao J, Lu M, Yu JW, Li YY, Shen L. Thymidine Phosphorylase/β-tubulin III expressions predict the response in Chinese advanced gastric cancer patients receiving first-line capecitabine plus paclitaxel. BMC Cancer. 2011;11(1):177.

    Article  PubMed  CAS  Google Scholar 

  12. Sève P, Mackey J, Isaac S, Trédan O, Souquet PJ, Pérol M, Lai R, Voloch A, Dumontet C. Class III β-tubulin expression in tumor cells predicts response and outcome in patients with non–small cell lung cancer receiving paclitaxel. Mol Cancer Ther. 2005;4(12):2001–7.

    Article  PubMed  Google Scholar 

  13. Ferrandina G, Zannoni GF, Martinelli E, Paglia A, Gallotta V, Mozzetti S, Scambia G, Ferlini C. Class III β-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients. Clin Cancer Res. 2006;12(9):2774–9.

    Article  PubMed  CAS  Google Scholar 

  14. Hasegawa S, Miyoshi Y, Egawa C, Ishitobi M, Taguchi T, Tamaki Y, Monden M, Noguchi S. Prediction of response to docetaxel by quantitative analysis of class I and III β-tubulin isotype mRNA expression in human breast cancers. Clin Cancer Res. 2003;9(8):2992–7.

    PubMed  CAS  Google Scholar 

  15. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.

    Article  PubMed  CAS  Google Scholar 

  16. Raspaglio G, Filippetti F, Prislei S, Penci R, De Maria I, Cicchillitti L, Mozzetti S, Scambia G, Ferlini C. Hypoxia induces class III beta-tubulin gene expression by HIF-1 [alpha] binding to its 3’flanking region. Gene. 2008;409(1–2):100–8.

    Article  PubMed  CAS  Google Scholar 

  17. Cicchillitti L, Penci R, Di Michele M, Filippetti F, Rotilio D, Donati MB, Scambia G, Ferlini C. Proteomic characterization of cytoskeletal and mitochondrial class III β-tubulin. Mol Cancer Ther. 2008;7(7):2070–9.

    Article  PubMed  CAS  Google Scholar 

  18. Katsetos CD, Dráberová E, Legido A, Dumontet C, Dráber P. Tubulin targets in the pathobiology and therapy of glioblastoma multiforme. I. class III β-tubulin. J Cell Physiol. 2009;221(3):505–13.

    Article  PubMed  CAS  Google Scholar 

  19. Ferlini C, Raspaglio G, Filippetti F, Mozzetti S, Riva A, Manzotti C, Scambia G. Class III beta-tubulin is transcriptionally regulated by hypoxia and HIF-1 alpha. In: Proceedings of the American Association for Cancer Research, 97th Annual Congress. 2006:2350.

  20. Levallet G, Bergot E, Antoine M, Creveuil C, Santos AO, Beau-Faller M, de Fraipont F, Brambilla E, Levallet J, Morin F, Westeel V, Whslez M, Quoix E, Debieuvre D, Dubois F, Rouquette I, Pujol JL, Moro-Sibilot D, Camonis J, Zalcman G. High TUBB3 Expression, an Independent Prognostic Marker in Patients with Early Non–Small Cell Lung Cancer Treated by Preoperative Chemotherapy, Is Regulated by K-Ras Signaling Pathway. Mol Cancer Ther. 2012;11(5):1203–13.

    Article  PubMed  CAS  Google Scholar 

  21. Baquero MT. Prognostic value of the microtubule stability index (MTSI), defined by the quantitative ratio of MAP-tau to stathmin expression, for outcome in breast cancer. J Clin Oncol, 2010 ASCO Aunual Meeting Proceedings. 2010:10523.

  22. Malet-Martino M, Martino R. Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review. Oncologist. 2002;7(4):288–323.

    Article  PubMed  CAS  Google Scholar 

  23. Lee S, Park YH, Kim KH, Cho EY, Ahn YC, Kim K, Shim YM, Ahn JS, Park K, Im YH. Thymidine synthase, thymidine phosphorylase, and excision repair cross-complementation group 1 expression as predictive markers of capecitabine plus cisplatin chemotherapy as first-line treatment for patients with advanced oesophageal squamous cell carcinoma. Br J Cancer. 2010;103(6):845–51.

    Article  PubMed  CAS  Google Scholar 

  24. Saito K, Khan K, Yu SZ, Ronson S, Rhee J, Li G, Van Echo D, Suntharalingam M, O’Malley BW Jr, Li D. The predictive and therapeutic value of thymidine phosphorylase and dihydropyrimidine dehydrogenase in capecitabine (Xeloda)-based chemotherapy for head and neck cancer. Laryngoscope. 2009;119(1):82–8.

    Article  PubMed  CAS  Google Scholar 

  25. Azuma K, Sasada T, Kawahara A, Takamori S, Hattori S, Ikeda J, Itoh K, Yamada A, Kage M, Kuwano M, Aizawa H. Expression of ERCC1 and class III β-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel. Lung Cancer. 2009;64(3):326–33.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported by Beijing Municipal Science & Technology Commission Program “Optimization of pharmacotherapy and individual selection in gastric cancer” (No. D101100050010023). The authors thank Dr. Ji-ping Yue (Infections and Cancer Biology Group, International Agency for Research on Cancer, Lyon, France) for critical reading of the manuscript.

Conflict of interest

The authors have no conflict of interest concerning this study.

Author information

Authors and Affiliations

  1. Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Gastrointestinal Oncology, Peking University Cancer Hospital and Institute, 52 Fucheng Road, Haidian District, Beijing, 100142, People’s Republic of China

    Jingwei Yu, Jing Gao, Zhihao Lu, Yilin Li & Lin Shen

Authors
  1. Jingwei Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jing Gao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zhihao Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yilin Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Lin Shen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lin Shen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yu, J., Gao, J., Lu, Z. et al. Serum levels of TUBB3 correlate with clinical outcome in Chinese patients with advanced gastric cancer receiving first-line paclitaxel plus capecitabine. Med Oncol 29, 3029–3034 (2012). https://doi.org/10.1007/s12032-012-0292-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12032-012-0292-y

Keywords

Search

Navigation